{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:35:07Z","timestamp":1789637707818,"version":"4.0.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016193","name":"University of Colorado School of Medicine, Anschutz Medical Campus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008028","name":"School of Medicine and Public Health, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010174","name":"University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.mcna.2023.06.017","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T15:10:57Z","timestamp":1691421057000},"page":"1035-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Updates for Pain Management and Opioid Use Disorder"],"prefix":"10.1016","volume":"107","author":[{"given":"Thomas","family":"Locke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Salisbury-Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Tyler","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcna.2023.06.017_bib1","first-page":"93","article-title":"How to Combat the Global Opioid Crisis","volume":"5","author":"Dennen","year":"2023","journal-title":"CPQ Neurol Psychol"},{"key":"10.1016\/j.mcna.2023.06.017_bib2","series-title":"Drug overdose deaths in the United States, 2001\u20132021. NCHS Data Brief, no 457","author":"Spencer","year":"2022"},{"issue":"No. RR-1","key":"10.1016\/j.mcna.2023.06.017_bib3","first-page":"1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"5","key":"10.1016\/j.mcna.2023.06.017_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/pds.4366","article-title":"Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review","volume":"27","author":"Coyle","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"No. RR-3","key":"10.1016\/j.mcna.2023.06.017_bib5","first-page":"1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.mcna.2023.06.017_bib6","unstructured":"Methadone Take-Home Flexibilities Extension Guidance. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance#:\u223c:text=On%20March%2016%2C%202020%2C%20SAMHSA,14%20days%20of%20Take%2DHome. Accessed 25 Jan 2023."},{"issue":"6","key":"10.1016\/j.mcna.2023.06.017_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.mcna.2023.06.017_bib8","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.mcna.2023.06.017_bib9","unstructured":"SAMHSA Extends the Methadone Take-Home Flexibility for One Year While Working Toward a Permanent Solution. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration from https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/202111181000. Accessed 26 Jan 2023."},{"issue":"3","key":"10.1016\/j.mcna.2023.06.017_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report","volume":"42","author":"Joudrey","year":"2021","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.mcna.2023.06.017_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","article-title":"Opioid treatment programs, telemedicine and COVID-19: A scoping review","volume":"43","author":"Chan","year":"2022","journal-title":"Subst Abus"},{"issue":"10","key":"10.1016\/j.mcna.2023.06.017_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.mcna.2023.06.017_bib13","doi-asserted-by":"crossref","first-page":"108896","DOI":"10.1016\/j.jsat.2022.108896","article-title":"Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic","volume":"143","author":"Hallgren","year":"2022","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.mcna.2023.06.017_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0740-5472(03)00188-0","article-title":"Distance traveled to outpatient drug treatment and client retention","volume":"25","author":"Beardsley","year":"2003","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mcna.2023.06.017_bib15","article-title":"Drug Enforcement Administration, Department of Justice","volume":"86 FR 33861","year":"2021","journal-title":"(Federal Register, The Daily Journal of the United States Government) Document Citation"},{"key":"10.1016\/j.mcna.2023.06.017_bib16","unstructured":"Consolidated Appropriations Act of 2023. Available at https:\/\/www.appropriations.senate.gov\/imo\/media\/doc\/JRQ121922.PDF. Accessed on 1 Mar 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib17","unstructured":"Drug Enforcement Administration, Department of Justice; 12 Jan 2023. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf. Accessed 13 Mar 2023."},{"issue":"7","key":"10.1016\/j.mcna.2023.06.017_bib18","doi-asserted-by":"crossref","first-page":"e2117128","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.mcna.2023.06.017_bib19","doi-asserted-by":"crossref","first-page":"e12880","DOI":"10.1002\/emp2.12880","article-title":"Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: A case series","volume":"4","author":"Spadaro","year":"2023","journal-title":"J\u00a0Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.mcna.2023.06.017_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of Buprenorphine\/Naloxone: A Review of the Literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.mcna.2023.06.017_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2023.06.017_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/dar.13049","article-title":"Understanding concurrent stimulant use among people on methadone: A qualitative study","volume":"39","author":"McNeil","year":"2020","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.mcna.2023.06.017_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: The surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2023.06.017_bib24","series-title":"Treatment of stimulant use disorders. SAMHSA publication No. PEP20-06-01-001","year":"2020"},{"key":"10.1016\/j.mcna.2023.06.017_bib25","doi-asserted-by":"crossref","first-page":"108307","DOI":"10.1016\/j.drugalcdep.2020.108307","article-title":"Contingency management for the treatment of methamphetamine use disorder: A systematic review","volume":"216","author":"Brown","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.mcna.2023.06.017_bib26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1360-0443.2009.02879.x","article-title":"Contingency management treatments: controversies and challenges","volume":"105","author":"Petry","year":"2010","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.mcna.2023.06.017_bib27","doi-asserted-by":"crossref","first-page":"e218049","DOI":"10.1001\/jamanetworkopen.2021.8049","article-title":"Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis","volume":"4","author":"Bentzley","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.mcna.2023.06.017_bib28","doi-asserted-by":"crossref","first-page":"108060","DOI":"10.1016\/j.drugalcdep.2020.108060","article-title":"Non-pharmacological interventions for methamphetamine use disorder: a systematic review","volume":"212","author":"AshaRani","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2023.06.017_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drugalcdep.2015.05.004","article-title":"An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness","volume":"153","author":"Murphy","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2023.06.017_bib30","unstructured":"Kaiser Family Foundation. Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State. Available at: https:\/\/www.kff.org\/medicaid\/issue-brief\/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state\/. Accessed 13 Mar 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib31","unstructured":"Montana Expanding Stimulant Use Disorder Treatment. Montana Department of Public Health and Human Services Available at: https:\/\/dphhs.mt.gov\/News\/2021\/09\/StimulantUseDisorder. Accessed 3 Feb 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib32","unstructured":"Recovery Incentives Program: California\u2019s Contingency Management Benefit. Department of Healthcare Services. Available at: https:\/\/www.dhcs.ca.gov\/Pages\/DMC-ODS-Contingency-Management.aspx. Accessed 2 Feb 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib33","unstructured":"California Health Care Foundation Issue Brief. Treating Stimulant Use Disorder: CalAIM\u2019s Contingency Management Pilot. Available at: https:\/\/www.chcf.org\/wp-content\/uploads\/2022\/05\/TreatingStimulantUseDisorderCalAIMsContingencyMgmtPilot.pdf. Access 13 Mar 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib34","unstructured":"Contingency Management (CM) project. Washington State Health Authority Available at: https:\/\/www.hca.wa.gov\/assets\/program\/contingency-mangement-fact-sheet.pdf. Accessed 3 Feb, 2023"},{"key":"10.1016\/j.mcna.2023.06.017_bib35","unstructured":"West Virginia Medicaid Section 1115 Waiver Demonstration: Evolving West Virginia Medicaid\u2019s Behavioral Health Continuum of Care Available at: 12.1.21.pdf\">https:\/\/dhhr.wv.gov\/bms\/Public%20Notices\/Documents\/20211201_SUD_Waiver_Extension_Application_Final%20Version%2012.1.21.pdf. Accessed 28 Feb 2023."},{"issue":"1","key":"10.1016\/j.mcna.2023.06.017_bib36","doi-asserted-by":"crossref","first-page":"e1920310","DOI":"10.1001\/jamanetworkopen.2019.20310","article-title":"Association between a state law allowing pharmacists to dispense naloxone without a prescription and naloxone dispensing rates","volume":"3","author":"Gangal","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.mcna.2023.06.017_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","article-title":"Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid","volume":"190","author":"Gertner","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2023.06.017_bib38","unstructured":"Pharmacists\u2019 Role in Naloxone Dispensing. Centers for Disease Control and Prevention National Center for Injury Prevention and Control. Available at: https:\/\/www.cdc.gov\/opioids\/naloxone\/factsheets\/pdf\/Naloxone_FactSheet_Pharmacists.pdf. Accessed 13 Mar 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib39","article-title":"A\u00a0drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered","volume":"19","author":"Silverman","year":"2018","journal-title":"Stat News"},{"key":"10.1016\/j.mcna.2023.06.017_bib40","unstructured":"US Department of Justice. Kaleo Inc. Agrees to Pay $12.7 Million to Resolve Allegations of False Claims for Anti-Overdose Drug. Available at: https:\/\/www.justice.gov\/opa\/pr\/kal-o-inc-agrees-pay-127-million-resolve-allegations-false-claims-anti-overdose-drug. Accessed 13 March 2023."},{"issue":"8","key":"10.1016\/j.mcna.2023.06.017_bib41","doi-asserted-by":"crossref","first-page":"e222663","DOI":"10.1001\/jamahealthforum.2022.2663","article-title":"Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010-2018","volume":"3","author":"Peet","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"5","key":"10.1016\/j.mcna.2023.06.017_bib42","first-page":"694","article-title":"Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies","volume":"60","author":"Spivey","year":"2020","journal-title":"J\u00a0Am Pharm Assoc 2003"},{"key":"10.1016\/j.mcna.2023.06.017_bib43","unstructured":"Clemans-Cope L. Naloxone Products and Their Pricing in Medicaid, 2010-2018. Urban Institute. Available at: https:\/\/www.urban.org\/sites\/default\/files\/publication\/102769\/naloxone-products-and-their-pricing-in-medicaid-2010-18.pdf, Accessed 7 February 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib44","doi-asserted-by":"crossref","first-page":"108355","DOI":"10.1016\/j.drugalcdep.2020.108355","article-title":"Medicaid prescription limits and their implications for naloxone accessibility","volume":"218","author":"Roberts","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2023.06.017_bib45","article-title":"FDA advisers recommend approval of over-the-counter naloxone to fight opioid overdose","volume":"15","author":"Facher","year":"2023","journal-title":"Stat News"},{"key":"10.1016\/j.mcna.2023.06.017_bib46","unstructured":"Naloxone Access: Summary of State Laws. Legislative Analysis and Public Policy Association Available at: Access-Summary-of-State-Laws.pdf\">http:\/\/legislativeanalysis.org\/wp-content\/uploads\/2023\/02\/Naloxone-Access-Summary-of-State-Laws.pdf, Accessed 7 February, 2023."},{"key":"10.1016\/j.mcna.2023.06.017_bib47","unstructured":"NEXT Distro Stay Alive, Stay Safe. Next Distro. Available at: https:\/\/nextdistro.org\/naloxone. Accessed 7 February 2023."},{"issue":"1","key":"10.1016\/j.mcna.2023.06.017_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-023-00732-x","article-title":"Remote harm reduction services are key solutions to reduce the impact of COVID-19-like crises on people who use drugs: evidence from two independent structures in France and in the USA","volume":"20","author":"Torres-Leguizamon","year":"2023","journal-title":"Harm Reduct J"},{"issue":"5","key":"10.1016\/j.mcna.2023.06.017_bib49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2019.7988","article-title":"Naloxone Co-prescribing to Patients Receiving Prescription Opioids in the Medicare Part D Program, United States, 2016-2017","volume":"322","author":"Jones","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mcna.2023.06.017_bib50","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1007\/s11606-020-06577-5","article-title":"Individual and Community Factors Associated with Naloxone Co-prescribing Among Long-term Opioid Patients: A Retrospective Analysis","volume":"36","author":"Stein","year":"2021","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.mcna.2023.06.017_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/20503245221112575","article-title":"State naloxone co-prescribing laws show mixed effects on overdose mortality rates","volume":"8","author":"Duska","year":"2022","journal-title":"Drug Science, Policy and Law"},{"issue":"6","key":"10.1016\/j.mcna.2023.06.017_bib52","first-page":"340","article-title":"Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?","volume":"47","author":"Weiner","year":"2021","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"10.1016\/j.mcna.2023.06.017_bib53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ajem.2018.05.044","article-title":"Naloxone Prescriptions from the Emergency Department: An Initiative in Evolution","volume":"37","author":"Verdier","year":"2019","journal-title":"Am J Emer Med"},{"issue":"6","key":"10.1016\/j.mcna.2023.06.017_bib54","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.5811\/westjem.2018.8.38829","article-title":"The emergency department as an opportunity for naloxone distribution","volume":"19","author":"Gunn","year":"2018","journal-title":"West J Emerg Med"},{"issue":"4","key":"10.1016\/j.mcna.2023.06.017_bib55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/ajhp\/zxaa409","article-title":"Point-of-care naloxone distribution in the emergency department: a pilot study","volume":"78","author":"Moore","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.mcna.2023.06.017_bib56","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.annemergmed.2020.02.013","article-title":"Take-home naloxone program implementation: lessons learned from seven Chicago-area hospitals","volume":"76","author":"Eswaran","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.mcna.2023.06.017_bib57","unstructured":"Centers for Disease Control and Prevention. Harm Reduction Available at: https:\/\/www.cdc.gov\/drugoverdose\/od2a\/case-studies\/harm-reduction.html. Accessed 13 Mar 2023."},{"issue":"3","key":"10.1016\/j.mcna.2023.06.017_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amepre.2022.04.021","article-title":"American College of Preventive Medicine: Addressing the Opioid Epidemic Through a Prevention Framework","volume":"63","author":"Livingston","year":"2022","journal-title":"Am J Prev Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:47:30Z","timestamp":1758419250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712523000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0025712523000998"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2023.06.017","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Updates for Pain Management and Opioid Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2023.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}